Himalaya Nutravedics IPO: dates, price band, lot size and GMP
Himalaya Nutravedics IPO listed on 29 Sep at ₹118 (BSE SME). Issue dates 22 – 24 Sep 2026, price band ₹100 – ₹106, lot 1,200 shares. The shares now trade on the exchange; any pre-IPO price on this site is historical.
Updated 6 Oct 2026, 14:11 IST. Dated dealer references.
BuyUnlistedShares tracks 197 IPOs on its calendar; the Himalaya Nutravedics IPO has a price band of ₹100 – ₹106, a lot of 1,200 shares and no grey-market premium reported yet as of 06 Oct 2026.
Key details
| Board | SME |
|---|---|
| Issue dates | 22 – 24 Sep 2026 |
| Price band | ₹100 – ₹106 |
| Lot size | 1,200 shares |
| Issue size | ₹26.50 Cr |
| Fresh issue | ₹25.16 Cr |
| Subscription | 2.33x |
| Registrar | Kfin Technologies Ltd. |
| Lead managers | Nirbhay Capital Services Pvt.Ltd. |
| Status | Listed |
Timeline
- Issue opens: 22 Sep
- Issue closes: 24 Sep
- Allotment: 25 Sep
- Refunds: 28 Sep
- Demat credit: 28 Sep
- Listing: 29 Sep
Live subscription
| Category | Subscribed |
|---|---|
| QIB | 1x |
| NII | 3.58x |
| sNII | 3.04x |
| bNII | 3.84x |
| Retail | 2.56x |
| Total | 2.33x |
Last updated 24 Sep 2026, 6:55 PM IST.
Issue details
| Face value | ₹10 |
|---|---|
| Issue type | Book Build Issue |
| Listing at | BSE SME |
| Market cap at the upper band | ₹93.35 Cr |
| P/E (pre-issue) | 9.04x |
| P/E (post-issue) | 12.63x |
| Fresh issue (shares) | 23,73,600 |
| Total shares offered | 23,73,600 |
| Promoter holding pre-issue | 95.14% |
| Promoter holding post-issue | 68.13% |
| Promoters | Rohit Asawa, Divya Asawa, Chanda Asawa, Rama Raju Penmatsa |
| Lead managers | Nirbhay Capital Services Pvt.Ltd. |
| Registrar phone | 040-79615565 |
| Registrar email | himalaya.ipo@kfintech.com |
| Company website | himalayanutravedics.com |
| Anchor bid date | 21 Sep 2026 |
| Anchor lock-in ends (50%) | 25 Oct 2026 |
| Anchor lock-in ends (remaining) | 24 Dec 2026 |
Lot sizes by investor category
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (minimum) | 2 | 2,400 | ₹2,54,400 |
| Retail (maximum) | 2 | 2,400 | ₹2,54,400 |
| sNII (minimum) | 3 | 3,600 | ₹2,54,400 |
| bNII (minimum) | 3 | 3,600 | ₹10,17,600 |
Reservation
| Category | Share of issue | Shares offered | Basis |
|---|---|---|---|
| Anchor Investor | 29.9% | 7,10,400 | |
| QIB | 20% | 4,74,000 | Not more than 50% of the Net Offer |
| NII (HNI) | 15% | 3,56,400 | Not less than 15% of the Net Offer |
| sNII | 5% | 1,18,800 | |
| bNII | 10% | 2,37,600 | |
| Retail | 35.1% | 8,32,800 | Not less than 35% of the Net Offer |
| Market Maker | 5.3% | 1,26,000 |
Subscription by day
| Day | QIB | NII | sHNI | bHNI | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 · 22 Sep | 0.00x | 0.14x | 0.21x | 0.10x | 0.16x | 0.11x |
| Day 2 · 23 Sep | 0.00x | 0.32x | 0.54x | 0.47x | 0.67x | 0.40x |
| Day 3 · 24 Sep | 1.00x | 3.58x | 3.04x | 3.84x | 2.56x | 2.33x |
Key ratios as of 31 Mar 2026
| EPS (pre-issue) | ₹11.72 |
|---|---|
| EPS (post-issue) | ₹8.39 |
| P/E (pre-issue) | 9.04x |
| P/E (post-issue) | 12.63x |
| RoNW | 45.12% |
| RoCE | 36.41% |
| RoE | 63.87% |
| PAT margin | 17.16% |
| EBITDA margin | 18.82% |
| Price / book | 3.97x |
| NAV per share | ₹26.7 |
| Debt / equity | 0.31 |
| Market cap (upper band) | ₹93.35 Cr |
Financials (₹ Cr)
| Metric | FY26 | FY25 | FY24 | FY26 vs FY25 |
|---|---|---|---|---|
| Assets | 24.42 | 10.82 | 6.09 | +125.7% |
| Total Income | 43.12 | 21 | 14.43 | +105.3% |
| Profit After Tax | 7.39 | 2.23 | 0.43 | +231.4% |
| EBITDA | 8.1 | 2.99 | 0.94 | +170.9% |
| NET Worth | 16.38 | 6.75 | 1.34 | +142.7% |
| Reserves and Surplus | 10.07 | 2.76 | 0.53 | +264.9% |
| Total Borrowing | 5.13 | 1.76 | 3.24 | +191.5% |
About Himalaya Nutravedics
Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India. In addition to its own branded products, the company also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies.
It offers a diversified product portfolio that includes classical Ayurvedic formulations based on traditional texts, proprietary Ayurvedic products, and nutraceutical supplements. These are available in multiple dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils.
The company operates through a hybrid business model, balancing its own-brand formulations with contract manufacturing services. It has an integrated in-house manufacturing facility located in Hyderabad, Telangana. As of September 2025, its products are distributed across multiple states in India, with a strong revenue presence in Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh.
Its product portfolio spans a wide range of wellness and therapeutic segments, including digestive health, immunity, metabolic health, musculoskeletal and joint care, reproductive health, respiratory wellness, pain management, and general well-being. These formulations are designed to support general wellness, nutritional supplementation, and lifestyle-related health needs, in line with applicable regulatory standards.
Objects of the issue
- Funding Working Capital Requirements — ₹13.75 Cr
- Business Development and Digital Marketing Activities — ₹7.5 Cr
- General Corporate Purposes
Net proceeds: ₹21.25 Cr
Peer comparison
| Company | EPS (Basic) | EPS (Diluted) | NAV (₹ per share) | P/E (x) | RoNW (%) | Financial statements |
|---|---|---|---|---|---|---|
| Himalaya Nutravedics India Ltd. (issuer) | 12.05 | 12.05 | 26.7 | — | 45.12% | — |
| Jeena Sikho Lifecare Ltd. | 17.84 | 17.81 | 37.6 | 26.75x | 27.67% | — |
| Sandu Pharmaceuticals Ltd. | 1.83 | 1.83 | 45.21 | 20.62x | 2.53% | — |
*The P/E Ratio has been computed based on the closing market price of equity shares on the BSE on August 31, 2026 divided by the Diluted EPS as on March 31, 2026, where EPS is adjusted for all the corporate actions upto May 11, 2026.
Strengths (per the offer document)
- Integrated multi-dosage manufacturing capability — Our Company operates an integrated manufacturing facility with the capability to manufacture a wide range of dosage forms, including medicated oils, soft gelatin capsules, hard gelatin capsules,…
- Doctor acceptance supported by product performance rather than mass advertising — Our Company’s Ayurvedic and Nutraceutical formulations have achieved repeat prescriptions and re-ordering by healthcare practitioners despite limited reliance on mass media or consumer-facing…
- Long-standing relationships with suppliers and customers — Our Company’s business model is characterised by repeat engagement with its customers across both sales of our branded products and third-party manufacturing operations.
- Geographic expansion achieved over a relatively short operating history — Since commencing business operations in September 2022, our Company has expanded its presence across multiple states in India within a relatively short period of time, achieving this scale within…
Risk factors (as disclosed by the company)
- We have historically derived, and may continue to derive, a significant portion of our supply from top 10 Suppliers — We have not entered into long-term agreements with our suppliers, and as a result, the success of our business is significantly dependent on the business terms and conditions with them, which may…
- We operate out of a single Manufacturing Facility, located at Hyderabad — As on the date of this Red Herring Prospectus, we operate out of a single Manufacturing Facility situated in Hyderabad, Telangana.
- Our Company is significantly dependent on the experience, expertise, and continued support of our Promoters for the growth and development of our business — Our Promoters have been instrumental in the formation, strategy, and overall business development of our Company.
- Our Registered and Corporate Office and Factory is located on the same premise, which is not owned by us and has been taken on a long term lease — with our lessor may adversely impact our operations and, consequently, our business, financial condition and results of operations.
- Our inability to accurately forecast demand for our products and manage our inventory may have an adverse effect on our business, results of operations — Our business depends on our estimate of the long-term demand for our products from our customers.
- Our business is subject to stringent and evolving labelling and regulatory requirements under applicable laws — Our Company is required to strictly comply with labelling, packaging, advertising and disclosure requirements prescribed under applicable laws and regulations governing Ayurvedic and health-related…
- There are certain discrepancies/errors/delayed-filings which have occurred in some of our corporate secretarial records relating to forms filed with the RoC… — As a company, we are required to file various statutory forms and returns with the Ministry of Corporate Affairs (“MCA”) in compliance with the provisions of the Companies Act, 2013.
- Products returned by Stockists upon expiry may adversely affect our revenues, margins and inventory management — Under our arrangements with Stockists, unsold products are returnable upon expiry.
From the RHP (strengths pages 181–182, risk factors pages 30–38). Headings shortened; the wording is the company’s. Not a recommendation.
Offer documents: DRHP (PDF) · RHP (PDF)
Track this issue
- Himalaya Nutravedics IPO GMP today and trend
- Himalaya Nutravedics IPO subscription status, day by day
- Himalaya Nutravedics IPO allotment status and how to check
Frequently asked questions
When does the Himalaya Nutravedics IPO open and close?
The issue is scheduled for 22 – 24 Sep 2026.
What is the Himalaya Nutravedics IPO price band?
The price band is ₹100 – ₹106 per share with a lot size of 1,200 shares.
How big is the Himalaya Nutravedics IPO?
The total issue size is ₹26.50 Cr.
When will Himalaya Nutravedics list?
The tentative listing date is 29 Sep on the SME platform.
How do I apply for the Himalaya Nutravedics IPO?
Apply through your broker or bank using ASBA or UPI within the issue window; the amount stays blocked in your account until allotment. BuyUnlistedShares does not take applications; it tracks the issue and the unlisted price before it.
Sources
- Draft red herring prospectus (DRHP), Himalaya Nutravedics · as filed with SEBI · bsesme.com
- Red herring prospectus (RHP), Himalaya Nutravedics · as filed · bseindia.com
- Registrar allotment page, Kfin Technologies Ltd. · allotment 25 Sep · ipostatus.kfintech.com
- BSE SME issues page · listing 29 Sep · bsesme.com
- Himalaya Nutravedics company website · himalayanutravedics.com
- BuyUnlistedShares IPO record: GMP, subscription and allotment, dated daily · GMP as of 29 Sep, 04:03 · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Himalaya Nutravedics IPO”, https://buyunlistedshares.com/ipo/himalaya-nutravedics-ipo, as of 06 Oct 2026.
Other IPOs on the calendar
- Paramount Syntex IPO · 30 Sep – 6 Oct 2026
- TNA Solutions IPO · 30 Sep – 6 Oct 2026
- Acme India Industries IPO · 30 Sep – 6 Oct 2026
- R.K.Fashion Accessories IPO · 5 – 7 Oct 2026
- Jio Platforms IPO · 21 – 23 Oct 2026
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk: the unlisted and pre-IPO dealing desk of Gayatri Financial Synergy, Faridabad, in the market since 2002. Reviewed by the BuyUnlistedShares desk before publishing. Data as of 06 Oct 2026.
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Ask · Community · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Part of the Gayatri Financial Synergy group (gayatrifin.com): AMFI-registered mutual fund distributor, Faridabad, since 2002.
